HIV, or Human Immunodeficiency Virus, is a type of virus that weakens the immune system, making one susceptible to a variety of infections. Although there is no cure for HIV, with the right treatment, ...

Researchers at UW are pioneering long-acting injectable HIV therapies that have the potential to simplify and expand ...

Professor Thumbi Ndung'u and his team at the Africa Health Research Institute are pioneering a study that explores innovative ...

The U.S. government has long been a leader in research and public health practice for preventing HIV infections. Since the start of the Trump administration in 2025, however, extensive cuts have been ...

SAN FRANCISCO — Data from two studies suggest that a once-daily combination therapy ... in a landmark trial of a drug that could transform the landscape of HIV prevention.

Pre-exposure prophylaxis, or PrEP, is part of the daily routine for a growing number of Canadians at risk of exposure to HIV through sex or injection drugs. While most people take it in pill ...

When lamivudine is used on its own to treat HIV, it can lead to drug resistance. It must be used in combination with other antiretroviral drugs for HIV. Like most drugs, lamivudine may cause mild ...

The once-a-year injectable pre-exposure prophylaxis (PrEP), Lenacapavir, has shown promising results in a recent Phase 1 clinical trial. The trial involved 40 healthy adults aged between 18 and 55 ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited.

In January, the White House ordered an immediate halt to the distribution of HIV medications by U.S.-funded foreign clinics, disrupting treatment for millions worldwide. AIDS activists ...